Delaware jury awards $96.3m damages to Natera over kidney transplant tests
Biotech firm CareDx found to have infringed one of two patents-in-suit through sale of AlloSure and AlloSeq | Damages award consists of $83.6m in lost profits and $12.6m in royalties.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
18 January 2024 Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal.
1 August 2023 The lawsuit alleged the unlawful use of cfDNA technology in RaDaR assay and related products | Adds to an existing legal action the company filed against Inivata.